5J·

Cellebrite Announces Leadership Change and Forecast Revision

Here's the hot stuff from the Cellebrite DI $CLBT (-1,41 %)
(NASDAQ: CLBT) Q2 2026 Earnings Release, fresh off the press:

🚀 Top-line Growth & ARR Dip

Cellebrite posted gains in revenue and profitability in the second quarter but fell slightly short of its own ARR target:

Revenue (Topline): Climbed by +16% to $131.1 million (within the guidance range of $130–133 million).

Annual Recurring Revenue (ARR): Rise to $507.8 million (+21% YoY). This put ARR just below the company’s own guidance range of $510–513 million.

Reason for the shortfall: Management cites longer sales cycles (longer sales cycles) as well as a slightly slower conversion rate for the new Inseyetsmigration.

🔮 Profitability beats estimates & margins are strong

Despite the slight slowdown in recurring revenue, operating leverage continues to improve margins:

Non-GAAP EPS: Stood at $0.11 per share , exceeding the analyst consensus ($0.07) by +$0.04.

Adjusted EBITDA: Reached $31.8 million (a solid margin of 24.2% vs. expected 22–23%).

GAAP Net Income: Amounted to $6.4 million (Non-GAAP net income: $29.7 million).

🤖 Leadership Change & Adjustment to Full-Year Forecast

High-Profile CEO Change:
Shiven Ramji (formerly President of Products & Technology) takes over as CEO from Thomas E. Hogan!

2026 Forecast Adjustment:
ARR adjustment: Annual target slightly lowered to $550 million to $560 million (previously $567–573 million, corresponding to approximately +14% to +16% growth).

Revenue Adjustment: Slightly adjusted to $555 million to $561 million (previously $565–571 million).

EBITDA increase: The full-year adjusted EBITDA target, however, was raised to $153 million to $159 million (previously $149–155 million)!

⚡ 💡 Jack’s take

A double-edged sword that could cause share price volatility in the short term: Operationally, Cellebrite is earning more money than Wall Street expected (an EPS beat of +4 cents) thanks to rock-solid EBITDA margins (24.2%). The downside lies in the ARR falling slightly short of expectations and the reduced annual revenue guidance due to longer deal cycles. However, the fact that Shiven Ramji—the former head of products—is stepping up to the top spot and that the EBITDA target for 2026 has been raised shows that the profitability machine is rock-solid!

13 Commentaires

Tenbagger2024@Tenbagger2024

Hey, has Jack written an analysis of my last performance yet? 😘

••

Brian@Aktienhauptmeister

@Tenbagger2024 Hi there, my dear, I'm a little short on time right now and haven't been able to get much done, which is why I didn't get around to the analysis 😅 But raketentoni did an excellent job after all!

•

Johannes@Johannes12345

Trade Republic: Time is running out—down nearly 30% 🙈😅

••

Voir toutes les 5 autres réponses

CaYaRo@CaYaRo

-32% because of a slight reduction in annual revenue guidance?

What else happened to trigger this drop?

••

Brian@Aktienhauptmeister

@CaYaRo A change in management was also an issue 🤷🏼‍♂️

••

H.S.@financial_ninja

Cellebrite remains one of the more interesting opportunities in our investment universe, but the Q2 2026 update changes the risk/reward profile.

The company cut its 2026 ARR and revenue guidance, while simultaneously raising its EBITDA outlook. At the same time, Thomas E. Hogan was replaced as CEO by Shiven Ramji, only three months after Ramji joined Cellebrite as President, Products & Technology.

The result is a classic situation: lower growth visibility, but an exceptionally strong underlying business available at a much lower valuation.

Key metrics

Metric 2026 view
Revenue guidance $555–561M
ARR guidance $550–560M
ARR growth 14–16%
Adjusted EBITDA $153–159M
Gross margin ~81%
Normalized FCF estimate ~$170M
Share price $9.93

The key disappointment is ARR growth, rather than profitability. Management cited longer sales cycles and lower expansion associated with Inseyets conversions.

Importantly, there is no clear evidence yet of structural deterioration in customer retention or the installed base.

⸻

Business Quality

Cellebrite operates in an unusually attractive niche: digital forensics and investigative intelligence for law enforcement, government, defense and intelligence organizations.

Its moat comes from the combination of:

* highly specialized technology;
* institutional trust;
* deep customer integration;
* forensic expertise;
* switching costs;
* regulatory and evidentiary requirements;
* a large installed base.

Gross margins above 80% and FCF margins above 30% reinforce the quality of the economics.

Business Quality Score: 88/100

⸻

Recurring Revenue & Growth

The recurring-revenue model remains one of the strongest aspects of the thesis.

Earlier in 2026, Cellebrite reported ARR growth above 20% and NRR of approximately 115%. The current guidance implies a significant slowdown, but management’s explanation points more towards sales-cycle timing and conversion issues than widespread customer losses.

Therefore, I would currently classify the slowdown as a meaningful warning, but not yet a broken thesis.

The critical metrics to monitor are:

ARR growth >15%
NRR >110–115%
Inseyets adoption
Genesis/AI monetization

⸻

Cash Flow & Balance Sheet

This is where the valuation becomes particularly compelling.

Cellebrite has historically generated roughly $160M of annual free cash flow, with very high cash conversion.

The balance sheet is also exceptionally strong, with roughly $500M+ of cash, deposits and investments and limited financial leverage.

At $9.93, the company is therefore being valued at only around 12–13x normalized FCF on an enterprise-value basis.

For a business with:

* 80% gross margins;
* 30% FCF margins;
* double-digit growth;
* recurring revenue;
* net cash;
* a strong competitive moat;

that valuation looks unusually low.

⸻

Leadership Change

The appointment of Shiven Ramji as CEO is the main new qualitative variable.

Ramji joined Cellebrite in May 2026 as President, Products & Technology, following senior experience in software and identity/cloud businesses.

The positive:

* strong product and technology background;
* direct exposure to Cellebrite’s strategy;
* potentially stronger focus on AI and platform development.

The negative:

* very limited tenure at Cellebrite;
* limited CEO track record within the company;
* transition coincides with the reduction in growth guidance.

I therefore classify leadership risk as elevated, but not as a thesis-breaking red flag.

Importantly, I do not give the new CEO a valuation premium yet. Any upside from better execution remains optionality until demonstrated in the numbers.

⸻

AI & Reinvestment Runway

This is arguably the most interesting part of the long-term thesis.

Cellebrite is attempting to evolve from a digital-forensics provider into a broader AI-powered investigative intelligence platform.

Genesis and other AI initiatives could eventually:

* increase ARPU;
* improve NRR;
* expand the TAM;
* increase switching costs;
* create additional software layers over the existing customer base.

Reinvestment Runway: 9/10

This provides meaningful upside to the base case, but I deliberately exclude most of that potential from today’s intrinsic value.

⸻

Valuation

Using a conservative DCF framework:

Bear case

$13–14

Assumes structurally slower growth and higher execution risk.

Base case

$17–18

Assumes growth gradually stabilizes around the mid-teens, strong FCF conversion and successful but not exceptional execution under Ramji.

Bull case

$23–26

Requires renewed ARR acceleration, strong AI/Genesis adoption, sustained margins and successful execution.

🎯 Fair Value: $17.50

At $9.93:

Upside to Fair Value: ~76%

Margin of Safety: ~43%

⸻

Scorecard

Factor Score
Business Quality 88/100
Moat 90/100
Recurring Revenue 90/100
Margins 94/100
FCF Generation 94/100
Balance Sheet 95/100
Reinvestment Runway 90/100
Management 76/100
Growth Visibility 72/100
Valuation 91/100

Investment Score: 87/100

🟢 STRONG BUY

At $9.93, Cellebrite qualifies as a Strong Buy.

The thesis is no longer based on exceptional near-term growth. It is based on exceptional business economics, strong recurring revenue, a powerful niche moat, substantial free cash flow and a very attractive valuation.

The main risks are now clear: slower ARR growth, execution under the new CEO, and stock-based compensation/dilution.

But at $9.93, the market appears to be pricing in a much weaker long-term outcome than I believe is warranted.

Conclusion: STRONG BUY — high-quality compounder temporarily penalized by a growth reset and leadership transition.

••

Dominik@Dome128

It's not really relevant, but could you do an analysis of jd.com?

••

Brian@Aktienhauptmeister

@Dome128 Here’s the hot stuff from JD.com $JD (NASDAQ: JD)’s Q2 2026 earnings release, fresh off the press:

🚀 Top-Line Performance & Service Boosters
JD.com $JD is showing a clear shift toward more profitable revenue streams in the second quarter of 2026, while its pure merchandise business is experiencing temporary headwinds:
Revenue Performance: Net revenue came in at 346.4 billion RMB (~51.1 billion USD) —a moderate year-over-year decline of -2.9%, primarily attributable to an extremely strong prior-year quarter (high base effect) and declines in the electronics segment (-11.8%).
Services segment as the driver: High-margin service revenues (Marketplace, Marketing & Logistics) climbed by +6.8% to 79.3 billion RMB, partially offsetting the decline in pure product sales.

🔮 Profitability Surge & Record Margins
Although top-line revenue declined slightly, the operating leverage is having a massive impact on profits:
Net income surge: Non-GAAP net income shot up by +20% YoY to 8.9 billion RMB (~1.3 billion USD). Non-GAAP EPS came in at 0.93 USD per ADS (above expectations).
Margin Expansion: The non-GAAP net margin improved from 2.1% in the same quarter last year to 2.6%. In the core JD Retail segment, an operating margin of 4.6% even set a new record for a major promotional quarter (6.18 Shopping Festival).

🤖 Loss Containment & Shareholder Returns
Discipline in New Businesses: Losses in the growth areas (JD Food Delivery, Jingxi) were significantly reduced, which noticeably supports the Group’s overall margin.
Massive Share Buybacks & FCF: Free cash flow for the last 12 months surged to 31.4 billion RMB (up from 10.1 billion RMB in the prior year). In addition, 1.0 billion USD was already spent on share buybacks in the first half of the year (~2.5% of all outstanding shares).

⚡ 💡 Jack’s Conclusion
JD.com provides definitive proof of its strategic shift: away from an unprofitable pursuit of revenue at any cost, toward relentless efficiency and profitability! Despite a subdued consumer climate in China, net income is growing at a double-digit rate, service revenue is scaling up, and management is consistently using the massive free cash flow for share buybacks. For those focused on value, strong cash flows, and operational leverage in e-commerce, this is a rock-solid investment!

••